

Medicaid Drug Rebate Agreements: Changes Require Immediate Action By Pharmaceutical Manufacturers

Prepared by:

Katy E. Koski, Andrew C. Yost, and James W. Matthews
Foley & Lardner LLP



LORMAN[®]

Published on www.lorman.com - October 2018

Medicaid Drug Rebate Agreements - Changes Require Immediate Action By Pharmaceutical Manufacturers, ©2018 Lorman Education Services. All Rights Reserved.

SERIES 2009

JA 2056
Treasury F. Gaith
Secretary of the Treasury

INTRODUCING

Lorman's New Approach to Continuing Education

ALL-ACCESS PASS

The All-Access Pass grants you **UNLIMITED** access to Lorman's ever-growing library of training resources:

- ☑ Unlimited Live Webinars - 120 live webinars added every month
- ☑ Unlimited OnDemand and MP3 Downloads - Over 1,500 courses available
- ☑ Videos - More than 1300 available
- ☑ Slide Decks - More than 2300 available
- ☑ White Papers
- ☑ Reports
- ☑ Articles
- ☑ ... and much more!

Join the thousands of other pass-holders that have already trusted us for their professional development by choosing the All-Access Pass.



Get Your All-Access Pass Today!

SAVE 20%

Learn more: www.lorman.com/pass/?s=special20

Use Discount Code Q7014393 and Priority Code 18536 to receive the 20% AAP discount.

*Discount cannot be combined with any other discounts.

Medicaid Drug Rebate Agreements: Changes Require Immediate Action By Pharmaceutical Manufacturers

Written by [KATY KOSKI](#), [ANDREW YOST](#) and [JAMES MATTHEWS](#) – 4/4/18

For the first time since the enactment of the Medicaid Drug Rebate Program (MDRP), the Centers for Medicare and Medicaid Services (CMS) revised the National Medicaid Drug Rebate Agreement (NDRA) entered into between drug manufacturers and the U.S. Department of Health and Human Services (HHS).

Drug manufacturers with existing active NDRA's now have until **September 30, 2018**, to execute and submit the revised NDRA if they wish to continue participating in the MDRP.

Published in the Federal Register (83 Fed. Reg. 12770 (Mar. 23, 2018)), the final revised NDRA contains several noteworthy changes from the version currently in effect including:

- **Incorporating the statutory and/or regulatory definitions for defined terms in the NDRA.** This is intended to ensure that the NDRA remains consistent with the statutory and regulatory framework governing the MDRP.
- **Imposing new reporting obligations on drug manufacturers.** Among other things, the revised NDRA requires *manufacturers* to calculate and report the Unit Rebate

Amount (URA) for their drug products, where previously CMS performed those calculations. In response to public comments, CMS explained that this added language is intended to “strengthen[]” CMS’s existing position that drug manufactures are responsible for making URA calculations.

- **Expanding the HHS Secretary’s audit authority to encompass all pricing data submitted.** Pursuant to section 1927(b)(3)(A) of the Social Security Act; in the original version, the Secretary’s audit authority is limited to Average Manufacturer Price and Best Price.
- **Revising penalties provisions.** In its penalties provisions, the revised NDRA now expressly provides that it does not limit the remedies available to the United States for a violation of the NDRA or any other law.

The MDRP is a complex system, involving the analysis and application of interrelated federal and state laws. The revisions listed above are not an exhaustive list of the changes found in the new NDRA. Manufacturers wishing to continue their participation in the MDRP now have six months to assess these changes and how they impact their operations and policies and to submit a new NDRA.

For more information on Foley’s Life Science and Health Care Industry Teams including the team, publications, and other materials, visit www.foley.com/life-sciences and foley.com/health-care.

The foregoing was prepared for general information purposes only. This information is not legal advice and is not to be acted upon as such.

The material appearing in this website is for informational purposes only and is not legal advice. Transmission of this information is not intended to create, and receipt does not constitute, an attorney-client relationship. The information provided herein is intended only as general information which may or may not reflect the most current developments. Although these materials may be prepared by professionals, they should not be used as a substitute for professional services. If legal or other professional advice is required, the services of a professional should be sought.

The opinions or viewpoints expressed herein do not necessarily reflect those of Lorman Education Services. All materials and content were prepared by persons and/or entities other than Lorman Education Services, and said other persons and/or entities are solely responsible for their content.

Any links to other websites are not intended to be referrals or endorsements of these sites. The links provided are maintained by the respective organizations, and they are solely responsible for the content of their own sites.